Jennifer Smith is the editor of Oncology Practice, part of MDedge Hematology/Oncology. She was previously the editor of Hematology Times, an editor at Principal Investigators Association, and a reporter at The Oneida Daily Dispatch. She has a BS in journalism.
News
Survival data reported from largest CAR T trial in B-cell lymphoma
ORLANDO – Progression-free survival results were best among complete responders and patients with primary mediastinal large B-cell lymphoma or...
News
Age, sex, and other factors linked to risk of intracranial hemorrhage in ITP
ORLANDO – Being older, male, and not having private insurance were some of the risk factors for intracranial hemorrhage among patients with immune...
News
Cancer researchers win grants from DOD, GO2 Foundation
The grants will support research on lung, breast, and bladder cancers.
News
Some MCL patients can safely stop venetoclax-ibrutinib, study suggests
ORLANDO - The study raises the possibility of limited-duration, targeted-agent therapy in relapsed/refractory mantle cell lymphoma.
News
KTE-X19 produces highest response rate in MCL subgroup
ORLANDO – The CAR T-cell therapy produced the highest reported response rate in mantle cell lymphoma patients who have failed treatment with a...
News
Orelabrutinib could be ‘preferred’ BTK inhibitor for MCL
ORLANDO – Orelabrutinib produced an 86% response rate in a phase 2 trial and appears to be safer than ibrutinib.
News
PT-Cy bests conventional GVHD prophylaxis
ORLANDO – Rates of progression/relapse, progression-free survival, and overall survival were similar between posttransplant cyclophosphamide and...
News
NFIX could be a target for sickle cell therapy
ORLANDO – Preclinical research suggests it may be a fetal hemoglobin repressor.
News
Off-the-shelf cellular therapy shows promise in the lab
ORLANDO – Findings from this preclinical research support moving forward with a phase 1 study of the therapy, as monotherapy or combined with...
Article
ASH to recognize researchers at annual meeting
Ten researchers will be honored at the 2019 annual meeting of the American Society of Hematology.
News
Combo elicits lasting responses in metastatic melanoma
NATIONAL HARBOR, MD. – In a phase 1/2 trial of previously untreated advanced melanoma patients, the combination of bempegaldesleukin and nivolumab...
News
Will TP53-mutated AML respond to immunotherapy?
NATIONAL HARBOR, MD. – Patients with TP53-mutated AML were shown to have increased immune infiltration, but it isn’t clear if they will respond...
News
Cleveland Clinic grants award, welcomes new talent
Dr. Brian Bolwell received the 2019 Alfred and Norma Lerner Humanitarian Award.
News
Researchers seek a way to predict cognitive deficits in children treated for ALL
Researchers are investigating gene variants and biomarkers that might correlate with chemotherapy-induced cognitive deficits.
News
Neoantigen vaccine appears safe and active in NSCLC
NATIONAL HARBOR, MD. – The vaccine produced only grade 1 adverse events and yielded responses in 7 of 24 patients,...